Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: A propensity analysis

Journal of the American Heart Association

Volumn 7, Issue 18, 2018, Pages

  Brisco Bacik, Meredith A ^a   Ter Maaten, Jozine M ^b   Houser, Steven R ^a   Vedage, Natasha A ^a   Rao, Veena ^c   Ahmad, Tariq ^c   Wilson, F Perry ^c,d   Testani, Jeffrey M ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute heart failure; Cardio renal syndrome; Diuretics; Metolazone; Worsening renal function

Indexed keywords

FUROSEMIDE; METOLAZONE; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ACUTE HEART FAILURE; ADJUVANT THERAPY; AGED; ALL CAUSE MORTALITY; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG MEGADOSE; ELECTRONIC MEDICAL RECORD; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; SINGLE DRUG DOSE; SURVIVAL; ACUTE DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DOSE RESPONSE; EPIDEMIOLOGY; FOLLOW UP; HEART FAILURE; HEART STROKE VOLUME; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ACUTE DISEASE; AGED; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEART FAILURE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METOLAZONE; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 85055613747     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.118.009149     Document Type: Article

References (31)

1. Adams K, Fonarow G, Emerman C, LeJemtel T, Costanzo M, Abraham W, Berkowitz R, Galvao M, Horton D. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216
2. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119:S3-S10
3. Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WHW. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7:261-270
4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation and American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;62:e240-e327
5. Heart Failure Society of A, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1-e194
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed). 2016;69:1167
7. Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005;19:301-306
8. Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994;71:146-150
9. Ng TM, Konopka E, Hyderi AF, Hshieh S, Tsuji Y, Kim BJ, Han SY, Phan DH, Jeng AI, Lou M, Elkayam U. Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. J Cardiovasc Pharmacol Ther. 2013;18:345-353
10. Kiyingi A, Field MJ, Pawsey CC, Yiannikas J, Lawrence JR, Arter WJ. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet. 1990;335:29-31
11. Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, Parissis J, Follath F, Peacock WF, Mebazaa A. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail. 2011;13:1244-1252
12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612
13. Testani JM, Mccauley BD, Chen J, Shumski M, Shannon RP. Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions. Cardiology. 2010;116:206-212
14. Brisco MA, Zile MR, Hanberg JS, Wilson FP, Parikh CR, Coca SG, Tang WH, Testani JM. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial. J Card Fail. 2016;22:753-760
15. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011;4:685-691
16. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int. 1984;26:183-189
17. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601-609
18. Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol. 2011;58:375-382
19. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139
20. Fillenbaum GG, Burchett BM, Blazer DG. Identifying a national death index match. Am J Epidemiol. 2009;170:515-518
21. Guo S, Fraser MW. Propensity Score Analysis: Statistical Methods and Applications, 2nd ed. Los Angeles: SAGE Publications, Inc; 2015
22. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, Fulkerson WJ Jr, Vidaillet H, Broste S, Bellamy P, Lynn J, Knaus WA. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA. 1996;276:889-897
23. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, Lewinter MM, Deswal A, Rouleau JL, Ofili EO. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805
24. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59:2145-2153
25. Rao V, Planavsky N, Hanberg JS, Ahmed T, Brisco-Bacik MA, Wilson FP, Jacoby D, Chen M, Wilson Tang WH, Cherney DZI, Ellison DH, Testani J. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol. 2017;28:3414-3424
26. Jentzer J, DeWald T, Hernandez A. Combination of loop diuretics with thiazidetype diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527-1534
27. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132-143
28. Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther. 1974;16:322-329
29. Steinmuller ST, Puschett JB. Effects of metolazone in man: comparison with chlorothiazide. Kidney Int. 1972;1:169-181
30. Moranville MP, Choi S, Hogg J, Anderson AS, Rich JD. Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance. Cardiovasc Ther. 2015;33:42-49
31. Li B, Evans D, Faris P, Dean S, Quan H. Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases. BMC Health Serv Res. 2008;8:12.